Selected research
Industry Research
Acute Myeloid Leukemia Drugs Industry Research Report 2026
Market perspective
The global Acute Myeloid Leukemia Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Acute Myeloid Leukemia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Acute Myeloid Leukemia Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Acute Myeloid Leukemia Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Acute Myeloid Leukemia Drugs include Takeda Pharmaceuticals, Eisai, Novartis, Eli Lilly and Company, Sunesis Pharmaceuticals, Otsuka Holdings, Genzyme Corporation, Clavis Pharma and Cephalon, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Acute Myeloid Leukemia Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Acute Myeloid Leukemia Drugs Market by Company
Takeda Pharmaceuticals
Eisai
Novartis
Eli Lilly and Company
Sunesis Pharmaceuticals
Otsuka Holdings
Genzyme Corporation
Clavis Pharma
Cephalon
Bristol Myers Squibb
Ambit Biosciences Corporation
Acute Myeloid Leukemia Drugs Segment by Type
Chemotherapy
Targeted Therapy
Other
Acute Myeloid Leukemia Drugs Segment by Application
Hospital
Clinic
Others
Acute Myeloid Leukemia Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acute Myeloid Leukemia Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Acute Myeloid Leukemia Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acute Myeloid Leukemia Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Acute Myeloid Leukemia Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Acute Myeloid Leukemia Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Acute Myeloid Leukemia Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Chemotherapy
- Targeted Therapy
- Other
Applications
- Hospital
- Clinic
- Others
Companies covered
- Takeda Pharmaceuticals
- Eisai
- Novartis
- Eli Lilly and Company
- Sunesis Pharmaceuticals
- Otsuka Holdings
- Genzyme Corporation
- Clavis Pharma
- Cephalon
- Bristol Myers Squibb
- Ambit Biosciences Corporation
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Acute Myeloid Leukemia Drugs Market Size (2021-2032)
- 2.2.2 Global Acute Myeloid Leukemia Drugs Sales (2021-2032)
- 2.2.3 Global Acute Myeloid Leukemia Drugs Market Average Price (2021-2032)
- 2.3 Acute Myeloid Leukemia Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Chemotherapy
- 2.3.3 Targeted Therapy
- 2.3.4 Other
- 2.4 Acute Myeloid Leukemia Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Acute Myeloid Leukemia Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Acute Myeloid Leukemia Drugs Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Acute Myeloid Leukemia Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Acute Myeloid Leukemia Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Acute Myeloid Leukemia Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Acute Myeloid Leukemia Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Acute Myeloid Leukemia Drugs, Product Type & Application
- 3.8 Global Manufacturers of Acute Myeloid Leukemia Drugs, Established Date
- 3.9 Global Acute Myeloid Leukemia Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Takeda Pharmaceuticals
- 4.1.1 Takeda Pharmaceuticals Company Information
- 4.1.2 Takeda Pharmaceuticals Business Overview
- 4.1.3 Takeda Pharmaceuticals Acute Myeloid Leukemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Takeda Pharmaceuticals Acute Myeloid Leukemia Drugs Product Portfolio
- 4.1.5 Takeda Pharmaceuticals Recent Developments
- 4.2 Eisai
- 4.2.1 Eisai Company Information
- 4.2.2 Eisai Business Overview
- 4.2.3 Eisai Acute Myeloid Leukemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Eisai Acute Myeloid Leukemia Drugs Product Portfolio
- 4.2.5 Eisai Recent Developments
- 4.3 Novartis
- 4.3.1 Novartis Company Information
- 4.3.2 Novartis Business Overview
- 4.3.3 Novartis Acute Myeloid Leukemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Novartis Acute Myeloid Leukemia Drugs Product Portfolio
- 4.3.5 Novartis Recent Developments
- 4.4 Eli Lilly and Company
- 4.4.1 Eli Lilly and Company Company Information
- 4.4.2 Eli Lilly and Company Business Overview
- 4.4.3 Eli Lilly and Company Acute Myeloid Leukemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Eli Lilly and Company Acute Myeloid Leukemia Drugs Product Portfolio
- 4.4.5 Eli Lilly and Company Recent Developments
- 4.5 Sunesis Pharmaceuticals
- 4.5.1 Sunesis Pharmaceuticals Company Information
- 4.5.2 Sunesis Pharmaceuticals Business Overview
- 4.5.3 Sunesis Pharmaceuticals Acute Myeloid Leukemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Sunesis Pharmaceuticals Acute Myeloid Leukemia Drugs Product Portfolio
- 4.5.5 Sunesis Pharmaceuticals Recent Developments
- 4.6 Otsuka Holdings
- 4.6.1 Otsuka Holdings Company Information
- 4.6.2 Otsuka Holdings Business Overview
- 4.6.3 Otsuka Holdings Acute Myeloid Leukemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Otsuka Holdings Acute Myeloid Leukemia Drugs Product Portfolio
- 4.6.5 Otsuka Holdings Recent Developments
- 4.7 Genzyme Corporation
- 4.7.1 Genzyme Corporation Company Information
- 4.7.2 Genzyme Corporation Business Overview
- 4.7.3 Genzyme Corporation Acute Myeloid Leukemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Genzyme Corporation Acute Myeloid Leukemia Drugs Product Portfolio
- 4.7.5 Genzyme Corporation Recent Developments
- 4.8 Clavis Pharma
- 4.8.1 Clavis Pharma Company Information
- 4.8.2 Clavis Pharma Business Overview
- 4.8.3 Clavis Pharma Acute Myeloid Leukemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Clavis Pharma Acute Myeloid Leukemia Drugs Product Portfolio
- 4.8.5 Clavis Pharma Recent Developments
- 4.9 Cephalon
- 4.9.1 Cephalon Company Information
- 4.9.2 Cephalon Business Overview
- 4.9.3 Cephalon Acute Myeloid Leukemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Cephalon Acute Myeloid Leukemia Drugs Product Portfolio
- 4.9.5 Cephalon Recent Developments
- 4.10 Bristol Myers Squibb
- 4.10.1 Bristol Myers Squibb Company Information
- 4.10.2 Bristol Myers Squibb Business Overview
- 4.10.3 Bristol Myers Squibb Acute Myeloid Leukemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Bristol Myers Squibb Acute Myeloid Leukemia Drugs Product Portfolio
- 4.10.5 Bristol Myers Squibb Recent Developments
- 4.11 Ambit Biosciences Corporation
- 4.11.1 Ambit Biosciences Corporation Company Information
- 4.11.2 Ambit Biosciences Corporation Business Overview
- 4.11.3 Ambit Biosciences Corporation Acute Myeloid Leukemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Ambit Biosciences Corporation Acute Myeloid Leukemia Drugs Product Portfolio
- 4.11.5 Ambit Biosciences Corporation Recent Developments
5 Global Acute Myeloid Leukemia Drugs Market Scenario by Region
- 5.1 Global Acute Myeloid Leukemia Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Acute Myeloid Leukemia Drugs Sales by Region: 2021-2032
- 5.2.1 Global Acute Myeloid Leukemia Drugs Sales by Region: 2021-2026
- 5.2.2 Global Acute Myeloid Leukemia Drugs Sales by Region: 2027-2032
- 5.3 Global Acute Myeloid Leukemia Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Acute Myeloid Leukemia Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Acute Myeloid Leukemia Drugs Revenue by Region: 2027-2032
- 5.4 North America Acute Myeloid Leukemia Drugs Market Facts & Figures by Country
- 5.4.1 North America Acute Myeloid Leukemia Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Acute Myeloid Leukemia Drugs Sales by Country (2021-2032)
- 5.4.3 North America Acute Myeloid Leukemia Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Acute Myeloid Leukemia Drugs Market Facts & Figures by Country
- 5.5.1 Europe Acute Myeloid Leukemia Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Acute Myeloid Leukemia Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Acute Myeloid Leukemia Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Acute Myeloid Leukemia Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Acute Myeloid Leukemia Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Acute Myeloid Leukemia Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Acute Myeloid Leukemia Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Acute Myeloid Leukemia Drugs Market Facts & Figures by Country
- 5.7.1 South America Acute Myeloid Leukemia Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Acute Myeloid Leukemia Drugs Sales by Country (2021-2032)
- 5.7.3 South America Acute Myeloid Leukemia Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Acute Myeloid Leukemia Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Acute Myeloid Leukemia Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Acute Myeloid Leukemia Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Acute Myeloid Leukemia Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Acute Myeloid Leukemia Drugs Sales by Type (2021-2032)
- 6.1.1 Global Acute Myeloid Leukemia Drugs Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Acute Myeloid Leukemia Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Acute Myeloid Leukemia Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Acute Myeloid Leukemia Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Acute Myeloid Leukemia Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Acute Myeloid Leukemia Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Acute Myeloid Leukemia Drugs Sales by Application (2021-2032)
- 7.1.1 Global Acute Myeloid Leukemia Drugs Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Acute Myeloid Leukemia Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Acute Myeloid Leukemia Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Acute Myeloid Leukemia Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Acute Myeloid Leukemia Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Acute Myeloid Leukemia Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Acute Myeloid Leukemia Drugs Value Chain Analysis
- 8.1.1 Acute Myeloid Leukemia Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Acute Myeloid Leukemia Drugs Production Mode & Process
- 8.2 Acute Myeloid Leukemia Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Acute Myeloid Leukemia Drugs Distributors
- 8.2.3 Acute Myeloid Leukemia Drugs Customers
9 Global Acute Myeloid Leukemia Drugs Analyzing Market Dynamics
- 9.1 Acute Myeloid Leukemia Drugs Industry Trends
- 9.2 Acute Myeloid Leukemia Drugs Industry Drivers
- 9.3 Acute Myeloid Leukemia Drugs Industry Opportunities and Challenges
- 9.4 Acute Myeloid Leukemia Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst